Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 15:40:22 23/05/2024 BST			5-day change	1st Jan Change
8.98 ^SEK	-0.22%		-3.44%	-2.81%

05-10	Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-23	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022

May 02, 2023 at 07:30 am

Initiator Pharma A/S reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was DKK 38.46 million compared to DKK 21.06 million a year ago. Basic loss per share from continuing operations was DKK 0.8 compared to DKK 0.6 a year ago.

Latest news about Initiator Pharma A/S

Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
Initiator Pharma Issues New Shares for Debt Conversion	02-21	MT
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	01-08	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	06/10/23	CI
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction	19/09/23	CI
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/08/23	CI
Initiator Pharma Wins EU Patent for Erectile Dysfunction, Depression Drug Candidate	09/08/23	MT
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression	09/08/23	CI
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial	18/07/23	CI
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.	05/07/23	CI
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine	29/06/23	CI
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction	05/06/23	CI
Initiator Pharma A/S's Equity Buyback announced on July 25, 2022 has expired.	25/05/23	CI
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	05/05/23	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	02/05/23	CI
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	02/05/23	CI
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018	06/03/23	CI
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations	20/12/22	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	04/11/22	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	04/11/22	CI
Initiator Pharma A/S Provides an Update on Its Clinical Programs	04/11/22	CI
Certain Ordinary Shares of Initiator Pharma A/S are subject to a Lock-Up Agreement Ending on 3-OCT-2022.	02/10/22	CI
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study	21/09/22	CI

Chart Initiator Pharma A/S

Duration

Period

More charts

Company Profile

Initiator Pharma A/S is a Denmark-based company engaged in the biotechnology sector. The Company focuses on developing drugs for treatment of erectile dysfunction.

Sector

Biotechnology & Medical Research

Calendar

23/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INITIATOR PHARMA A/S	-2.81%	44.38M
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research